blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3898611

EP3898611 - SUBSTITUTED OXOPYRIDINE DERIVATIVES FOR THE TREATMENT AND/OR PROPHYLAXIS OF THROMBOTIC OR THROMBOEMBOLIC DISORDERS AND/OR THROMBOTIC OR THROMBOEMBOLIC COMPLICATIONS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  26.01.2024
Database last updated on 07.10.2024
FormerExamination is in progress
Status updated on  30.03.2023
FormerRequest for examination was made
Status updated on  24.09.2021
FormerThe international publication has been made
Status updated on  02.07.2020
Formerunknown
Status updated on  14.12.2019
Most recent event   Tooltip26.01.2024Application deemed to be withdrawnpublished on 28.02.2024  [2024/09]
Applicant(s)For all designated states
Bayer Aktiengesellschaft
Kaiser-Wilhelm-Allee 1
51373 Leverkusen / DE
[2021/43]
Inventor(s)01 / HEITMEIER, Stefan
Am Wasserturm 56
42489 Wülfrath / DE
02 / MUNDL, Hardi
Leisberg 8
69124 Heidelberg / DE
 [2021/43]
Representative(s)BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 50
40789 Monheim am Rhein / DE
[N/P]
Former [2021/43]BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 10
40789 Monheim am Rhein / DE
Application number, filing date19813886.910.12.2019
[2021/43]
WO2019EP84449
Priority number, dateEP2018021321617.12.2018         Original published format: EP 18213216
[2021/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020126682
Date:25.06.2020
Language:EN
[2020/26]
Type: A1 Application with search report 
No.:EP3898611
Date:27.10.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 25.06.2020 takes the place of the publication of the European patent application.
[2021/43]
Search report(s)International search report - published on:EP25.06.2020
ClassificationIPC:C07D401/10, A61K31/4439, A61P9/10
[2021/43]
CPC:
C07D401/10 (EP,KR,US); A61K31/4439 (EP,KR); A61K9/10 (EP);
A61K9/2018 (EP); A61P9/10 (EP,KR,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/43]
TitleGerman:SUBSTITUIERTE OXOPYRIDINDERIVATE ZUR BEHANDLUNG UND/ODER PROPHYLAXE VON THROMBOTISCHEN ODER THROMBOEMBOLISCHEN ERKRANKUNGEN UND/ODER THROMBOTISCHEN ODER THROMBOEMBOLISCHEN KOMPLIKATIONEN[2021/43]
English:SUBSTITUTED OXOPYRIDINE DERIVATIVES FOR THE TREATMENT AND/OR PROPHYLAXIS OF THROMBOTIC OR THROMBOEMBOLIC DISORDERS AND/OR THROMBOTIC OR THROMBOEMBOLIC COMPLICATIONS[2021/43]
French:DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS POUR LE TRAITEMENT ET/OU LA PROPHYLAXIE DE TROUBLES THROMBOTIQUES OU THROMBOEMBOLIQUES ET/OU DE COMPLICATIONS THROMBOTIQUES OU THROMBOEMBOLIQUES[2021/43]
Entry into regional phase19.07.2021National basic fee paid 
19.07.2021Designation fee(s) paid 
19.07.2021Examination fee paid 
Examination procedure19.07.2021Examination requested  [2021/43]
19.07.2021Date on which the examining division has become responsible
20.01.2022Amendment by applicant (claims and/or description)
29.03.2023Despatch of a communication from the examining division (Time limit: M06)
10.10.2023Application deemed to be withdrawn, date of legal effect  [2024/09]
02.11.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2024/09]
Fees paidRenewal fee
30.11.2021Renewal fee patent year 03
29.11.2022Renewal fee patent year 04
02.01.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2016205482  (BRISTOL MYERS SQUIBB CO [US]) [Y] 1-10* page 54, line 3 - line 29; example -; claim - *;
 [XDY]WO2017005725  (BAYER PHARMA AG [DE]) [XD] 1-10 * page 46, line 20 - page 47, line 30; examples 235, 242; claim - * [Y] 1-10;
 [Y]US2017029423  (WEI YONGGANG [CN], et al) [Y] 1-10 * paragraph [[0015]]; example -; claim - *;
 [Y]WO2017023992  (BRISTOL MYERS SQUIBB CO [US]) [Y] 1-10 * page 24, line 11 - line 21; example -; claim - *
by applicantWO2017005725
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.